Compare CINT & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | CADL |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.1M | 578.8M |
| IPO Year | 2021 | 2021 |
| Metric | CINT | CADL |
|---|---|---|
| Price | $3.38 | $7.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $7.35 | ★ $19.00 |
| AVG Volume (30 Days) | 99.0K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | $16.69 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.51 | $4.35 |
| 52 Week High | $6.31 | $9.27 |
| Indicator | CINT | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 27.21 | 58.29 |
| Support Level | N/A | $4.91 |
| Resistance Level | $5.01 | $9.27 |
| Average True Range (ATR) | 0.22 | 0.65 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 3.85 | 30.53 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.